April 22 - 26, 2024
Seattle, Washington
May 7 - 9, 2024 (Virtual)

Event Supporters

2024 MRS Spring Meeting
SB06.08.03

Incorporation of Gentamicin-Encapsulated Poly (lactic-co-glycolic acid) Nanoparticles into Polyurethane/Poly (ethylene oxide) Nanofiber Scaffolds for Biomedical Applications

When and Where

Apr 25, 2024
2:15pm - 2:30pm
Room 427, Level 4, Summit

Presenter(s)

Co-Author(s)

Yu Sun1,Jesse Heacock1,Yan Li1,Jiangguo Liu1,Chuchu Chen2,Kaiyan Qiu2

Colorado State University1,Washington State University2

Abstract

Yu Sun1,Jesse Heacock1,Yan Li1,Jiangguo Liu1,Chuchu Chen2,Kaiyan Qiu2

Colorado State University1,Washington State University2
The development of novel wound-dressing materials has attracted significant research interests in recent years. With the advancement of nanofabrication, the application of nanoparticles (NPs) in drug delivery systems has become feasible. However, most existing work focuses on incorporation of metal, metal/semi-metal oxide, or organic particles into nanofiber scaffolds. There has been a lack of work on incorporation of drug-encapsulated polymeric particles into nanofiber scaffolds. In this study, gentamicin-encapsulated poly (lactic-co-glycolic acid) (PLGA) NPs were synthesized via a double emulsion solvent evaporation method. Electrospinning was used to incorporate gentamicin-encapsulated PLGA NPs into nanofiber scaffolds. Atomic force microscopy (AFM), dynamic light scattering, scanning electron microscopy (SEM), ultraviolet-visible spectroscopy (UV-vis), and an agar diffusion method were utilized to characterize the morphologies, release profiles, and antibacterial activities of various gentamicin-loaded PLGA NPs incorporated nanofiber scaffolds. The results indicated the PLGA NPs had a spherical morphology with an average diameter of 130nm. Purification of PLGA NPs was essential to eliminate the residual polyvinyl alcohol (PVA) and to prevent particle agglomeration. The purified PLGA NPs were uniformly and individually incorporated into the polyurethane (PU)/ poly ethenyl oxide (PEO) or PEO-only nanofiber scaffolds, but nearly none into the PU-only fiber scaffolds. PEO served as a continuous phase in the PU/PEO mixture, which significantly improved the compatibility of PLGA NPs and PU, resulting in a well-dispersed distribution of PLGA NPs in the monolithic nanofiber scaffolds. Excellent antibacterial properties against <i>E.coli </i>were found in both PU/PEO and PEO nanofiber scaffolds. This study of incorporating gentamicin-encapsulated PLGA NPs into fiber scaffolds provides insights for achieving successful incorporation of drugs-encapsulated polymeric NPs into fiber scaffolds. This offers a promising microfabrication technology for delivery of therapeutic molecules with controlled release for biomedical applications.

Keywords

microstructure | polymer | tissue

Symposium Organizers

Neel Joshi, Northeastern University
Eleni Stavrinidou, Linköping University
Bozhi Tian, University of Chicago
Claudia Tortiglione, Istituto di Scienze Applicate e Sistemi Intelligenti

Symposium Support

Bronze
Cell Press

Session Chairs

Maria Rosa Antognazza
Claudia Tortiglione

In this Session